Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Erythrocytosis Post Allogeneic Stem Cell Transplantation, An Observational Study Of Hemoglobin Levels On Long-Term Follow Up Post Transplantation In Patients With Fanconi Or Acquired Aplastic Anemia

Mouhab Ayas, MD, Khawar Siddiqui, MSc, Abdulrahman Al-Musa, MD, Hassan El-Solh, MD, Abdullah Al-Jefri, MD, Ali Al-Ahmari, MD, Ashraf Khairi, MD, Samer Markiz, MD, Amal Mohamad, RN, Amal Al-Seraihy

Blood (2013) 122 (21): 4643.

https://doi.org/10.1182/blood.V122.21.4643.4643

Published: 2013

Journal Articles

Factors Affecting Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia.

Mouhab F Ayas, MD, Khawar Siddiqui, MSc, Amal Al-Seraihy, MD, Hassan El-Solh, MD, Ali Al-Ahmari, MD, Abdulrahman Al-Musa, MD, Ashraf Khairi, MD, Samer Markiz, MD, Hasan Shahin, MD, Viqaruddin Mohammed, Abdullah Al-Jefri, MD

Blood (2012) 120 (21): 3100.

https://doi.org/10.1182/blood.V120.21.3100.3100

Published: 2012

Journal Articles

Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)

Blood (2012) 119 (25): 6016–6024.

https://doi.org/10.1182/blood-2011-12-398958

Published: 2012

Includes: Supplemental data

Journal Articles

Cytogenetic Risk Remains a Major Predictor of Outcome in Pediatric AML and ALL Treated with Allogeneic Stem Cell Transplantation,

Claudia Ulrike Walter, PhD, Mouhab Ayas, Amal Alseraihy, M.D., Hassan El-Solh, MD, Abdullah Al-Jefri, M.D., Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Maher Albitar, M.D.

Blood (2011) 118 (21): 3524.

https://doi.org/10.1182/blood.V118.21.3524.3524

Published: 2011

Journal Articles

CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,

Maher Albitar, M.D., Amal Alseraihy, M.D., Mouhab Ayas, Abdullah Al-Jefri, M.D., Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Claudia Ulrike Walter, PhD, Randa Nounou, M.D., Salem Khalil, M.D., Nasir Bakshi, M.D., Tarek Owaidah, MD, FRCPA, Hassan El-Solh, MD

Blood (2011) 118 (21): 3525.

https://doi.org/10.1182/blood.V118.21.3525.3525

Published: 2011

Journal Articles

Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,

Mahmoud Aljurf, M.D., Hala Abalkhail, PhD, Amal Alseraihy, M.D., Mouhab Ayas, Abdullah Al-Jefri, M.D., Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Claudia Ulrike Walter, PhD, Naeem A. Chaudhri, MD, FACP, Fahed Almhareb, MBBS, FACP, Hassan El-Solh, MD, Maher Albitar, M.D.

Blood (2011) 118 (21): 3533.

https://doi.org/10.1182/blood.V118.21.3533.3533

Published: 2011

Journal Articles

CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,

Blood (2011) 118 (21): 4092.

https://doi.org/10.1182/blood.V118.21.4092.4092

Published: 2011

Journal Articles

The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults

Hala Abalkhail, PhD, Hassan El-Solh, MD, Amal Alseraihy, M.D., Mouhab Ayas, Ali Al-Ahmari, MD, Asim F Belgaumi, MD, Abdullah Al-Jefri, M.D., Ola Altombakty, MT, Mohammed Toulimat, MT, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 5237.

https://doi.org/10.1182/blood.V118.21.5237.5237

Published: 2011

Journal Articles

Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population

Hala Abalkhail, PhD, Hassan El-Solh, MD, Amal Alseraihy, M.D., Asim F Belgaumi, MD, Abdullah Al-Jefri, M.D., Mouhab Ayas, Ali Al-Ahmari, MD, Fahed Almhareb, MBBS, FACP, Naeem A. Chaudhri, MD, FACP, Claudia Ulrike Walter, PhD, Mahmoud Aljurf, M.D., Maher Albitar, M.D.

Blood (2011) 118 (21): 5239.

https://doi.org/10.1182/blood.V118.21.5239.5239

Published: 2011

Journal Articles

Noval Mutation in Four Saudi Families with Glanzmann Thrombasthenia

Tarek Owaidah, MD, FRCPA, Hala Abalkhail, PhD, Abdulrahman Al Musa, Hasan Mosmali, Albanyan Abdulmajeed, Abdullah Al Jefri, MD, Randa alNounou, Hazzaa Al Zahrani, Mahasen Saleh, MD

Blood (2011) 118 (21): 1136.

https://doi.org/10.1182/blood.V118.21.1136.1136

Published: 2011

Journal Articles

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Timothy G St Pierre, PhD, Amal El-Beshlawy, MD, Mohsen Saleh Elalfy, MD, Abdullah Al Jefri, MD, Kusai Al Zir, MD, Shahina Daar, MD, Dany Habr, MD, Ulrike Kriemler-Krahn, Ali Taher, MD

Blood (2010) 116 (21): 2053.

https://doi.org/10.1182/blood.V116.21.2053.2053

Published: 2010

Journal Articles

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dany Habr, Abdel Hmissi, Amal El-Beshlawy

Blood (2008) 112 (11): 3879.

https://doi.org/10.1182/blood.V112.11.3879.3879

Published: 2008

Journal Articles

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Ali Taher, Amal El-Beshlawy, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Blood (2008) 112 (11): 5409.

https://doi.org/10.1182/blood.V112.11.5409.5409

Published: 2008

Journal Articles

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dietrich Pfluger, Dominik Hadler, Amal El-Beshlawy

Blood (2007) 110 (11): 2779.

https://doi.org/10.1182/blood.V110.11.2779.2779

Published: 2007

Journal Articles

Deferasirox (Exjade ® , ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.

Ali Taher, Amal El-Beshlawy, Abdullah Al Jefri, Mohsen El Alfy, Kusai Al Zir, Shahina Daar, Ghazi Al-Damanhouri, Dietrich Hadler, Ulrike Krahn

Blood (2005) 106 (11): 3840.

https://doi.org/10.1182/blood.V106.11.3840.3840

Published: 2005

NARROW

Erythrocytosis Post Allogeneic Stem Cell Transplantation, An Observational Study Of Hemoglobin Levels On Long-Term Follow Up Post Transplantation In Patients With Fanconi Or Acquired Aplastic Anemia

Factors Affecting Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia.

Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)

Cytogenetic Risk Remains a Major Predictor of Outcome in Pediatric AML and ALL Treated with Allogeneic Stem Cell Transplantation,

CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,

Chimerism Analysis of Free Circulating DNA in the Prediction of Relapse in Patients with Acute Leukemia Treated with Stem Cell Transplantation,

CD11b Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,

The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults

Most Risk-Stratification Molecular Markers in Acute Myeloid Leukemia (AML) Are Rarely Found in Early Childhood AML in the Middle Eastern Population

Noval Mutation in Four Saudi Families with Glanzmann Thrombasthenia

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Deferasirox (Exjade ® , ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only